Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

PURPOSE To provide evidence-based recommendations updating the 2017 ASCO
guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Background Icotinib has provided survival benefits for patients with advanced, epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to …

Background Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …

The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …

The epidemiology and aetiology of drug‐induced liver injury (DILI) vary across different
countries and populations. Overall, DILI is rare in the general population but has become …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …